John Curnutte

John has had an extensive career as a clinician, researcher, and drug development executive, bringing industry-leading expertise in advancing novel therapies through research and development and treating patients in need. Most recently, he served as executive vice president of research and development for Portola Pharmaceuticals, where he worked as the lead executive officer for all R&D activities. Prior to joining Portola, John served as chief executive officer at 3-V Biosciences and as president of the Research Institute at Schering-Plough Biopharma, where he helped progress eight therapeutic candidates into development. He began his biopharmaceutical career at Genentech, where he oversaw their immunology discovery research program. John’s clinical and research experience includes appointments at Massachusetts General Hospital, the Dana-Farber Cancer Institute, University of Michigan Medical School, The Scripps Research Institute, and Stanford University School of Medicine. He currently serves on the board of directors of Pliant Therapeutics.

John holds an A.B. in biochemistry and molecular biology from Harvard University and an M.D. and Ph.D. in biological chemistry from Harvard Medical School.